During the past decade, Retinal Research Institute, LLC conducted 42 clinical trials. In the 10-year time frame, 42 clinical trials started and 17 clinical trials were completed, i.e. on average, 40.5% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 17 clinical trials were completed. i.e. 77.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retinal Research Institute, LLC" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Kodiak Sciences Inc" with 6 trials sponsored, "Clearside Biomedical, Inc." with 3 trials sponsored, "Aerie Pharmaceuticals" with 2 trials sponsored and "Apellis Pharmaceuticals, Inc." with 2 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retinal Research Institute, LLC" #1 collaborator was "Chugai Pharmaceutical" with 2 trials as a collaborator, "Novartis Pharmaceuticals" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator and "Stada Arzneimittel AG" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Retinal Research Institute, LLC" are "Diabetic Macular Edema" (9 trials), "Geographic Atrophy" (6 trials), "Macular Edema" (6 trials), "Macular Degeneration" (5 trials) and "Retinal Vein Occlusion" (5 trials). Many other conditions were trialed in "Retinal Research Institute, LLC" in a lesser frequency.

Most popular intervention types in "Retinal Research Institute, LLC" are "Drug" (39 trials), "Other" (10 trials), "Procedure" (4 trials), "Biological" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (12 trials), "Aflibercept" (10 trials), "Faricimab" (6 trials), "KSI-301" (6 trials) and "Ranibizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Retinal Research Institute, LLC" are 42 trials for "All" genders.

Currently, there are NaN active trials in "Retinal Research Institute, LLC". undefined are not yet recruiting, 3 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in Retinal Research Institute, LLC, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Retinal Research Institute, LLC, 4 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".